JP2018503355A5 - - Google Patents

Info

Publication number

JP2018503355A5

JP2018503355A5 JP2017523423A JP2017523423A JP2018503355A5 JP 2018503355 A5 JP2018503355 A5 JP 2018503355A5 JP 2017523423 A JP2017523423 A JP 2017523423A JP 2017523423 A JP2017523423 A JP 2017523423A JP 2018503355 A5 JP2018503355 A5 JP 2018503355A5

Authority

JP

Japan

Prior art keywords

fusion protein

seq

protein according

motomeko

item

Prior art date

2015-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108020001507 fusion proteins Proteins 0.000 claims description 143
• 102000037865 fusion proteins Human genes 0.000 claims description 143
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
• 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims description 33
• 102000044507 human SERPING1 Human genes 0.000 claims description 33
• 230000035772 mutation Effects 0.000 claims description 22
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
• 230000000694 effects Effects 0.000 claims description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
• 150000001413 amino acids Chemical class 0.000 claims description 3
• 230000009089 cytolysis Effects 0.000 claims description 3
• 210000003743 erythrocyte Anatomy 0.000 claims description 3
• 238000000338 in vitro Methods 0.000 claims description 3
• 108091006020 Fc-tagged proteins Proteins 0.000 claims description 2
• 108091005804 Peptidases Proteins 0.000 claims description 2
• 239000004365 Protease Substances 0.000 claims description 2
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
• 239000000539 dimer Substances 0.000 claims description 2
• 239000012636 effector Substances 0.000 claims description 2
• 230000008030 elimination Effects 0.000 claims 2
• 238000003379 elimination reaction Methods 0.000 claims 2
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 102000009027 Albumins Human genes 0.000 description 11
• 108010088751 Albumins Proteins 0.000 description 11
• 210000004027 cell Anatomy 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 9
• 102000004196 processed proteins & peptides Human genes 0.000 description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 206010059284 Epidermal necrosis Diseases 0.000 description 2
• 206010019860 Hereditary angioedema Diseases 0.000 description 2
• 102000008100 Human Serum Albumin Human genes 0.000 description 2
• 108091006905 Human Serum Albumin Proteins 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 208000030886 Traumatic Brain injury Diseases 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 238000000034 method Methods 0.000 description 2
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 230000009450 sialylation Effects 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009529 traumatic brain injury Effects 0.000 description 2
• 102000016917 Complement C1 Human genes 0.000 description 1
• 108010028774 Complement C1 Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 101150050927 Fcgrt gene Proteins 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1